Author

Don Arlen Brigham

Observed names: D.A. Brigham, DON A. BRIGHAM, Don A. Brigham, Don A Brigham, Don A. Brigham, Don Brigham

Observed institution: Sarcoma Oncology Center

OpenAlex ID: A5091737953

SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma

2023 · Erlinda Maria Gordon, Sant P. Chawla, et al. · Cancers · 36

PDF

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)

2023 · Sant P. Chawla, Walter Andree Tellez, et al. · Frontiers in Oncology · 19

PDF

SAINT: Results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.

2019 · Erlinda Maria Gordon, Victoria S. Chua-Alcala, et al. · Journal of Clinical Oncology · 9

Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies (IND# 19130)

2022 · Sant P. Chawla, Steven Wong, et al. · Frontiers in Molecular Medicine · 7

PDF

Long Term Survival Following DeltaRex-G/DeltaVax Tumor-Targeted Gene Therapy for Advanced Chemotherapy-Resistant Malignancies: An Academic Milestone

2021 · Seiya Liu, Sant P. Chawla, et al. · Clinics in Oncology · 7

Five-year results of a phase 2 trial using ipilimumab (I), nivolumab (N), and trabectedin (T) for previously untreated advanced soft tissue sarcoma (NCT03138161).

2022 · Erlinda Maria Gordon, Sant P. Chawla, et al. · Journal of Clinical Oncology · 6

Early-stage CCNG1+ HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, a CCNG1 Inhibitor

2023 · SANT P. CHAWLA, OLGA OLEVSKY, et al. · Anticancer Research · 3

PDF

Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast

2023 · Howard W. Bruckner, Sant P. Chawla, et al. · Frontiers in Molecular Medicine · 3

PDF

1483O Results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma

2022 · E. Gordon, W.A. Tellez, et al. · Annals of Oncology · 3

A phase 2 study using ipilimumab, nivolumab, and trabectedin for previously untreated metastatic soft tissue sarcoma.

2021 · Erlinda Maria Gordon, Victoria S. Chua, et al. · Journal of Clinical Oncology · 3

From Mendel to Gene Therapy

2023 · SAMANTHA L. JEFFREY, DON A. BRIGHAM, et al. · Anticancer Research · 2

PDF

Abstract 5183: Retrospective analysis of CCNG1 expression in tumors, a novel biomarker in development for partnering with DRG-101, a tumor targeted retrovector encoding a CCNG1 inhibitor gene

2024 · Nadezhda Omelchenko, Vaishali Kumar, et al. · Cancer Research · 1

Interim results of a phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma.

2023 · Neal Shiv Chawla, Nadezhda Omelchenko, et al. · Journal of Clinical Oncology · 1

Immune and Cell Cycle Checkpoint Inhibitors for Cancer Immunotherapy

2021 · Erlinda M. Gordon, Nicole L. Angel, et al. · IntechOpen eBooks · 1

PDF

Control of Metastatic Tumor Growth in a Patient with Sporadic Metastatic Malignant Peripheral Nerve Sheath Tumor (sMPNST) Using the Hope Protocol, an Alternative Treatment Regimen for Cancer

2021 · Erlinda Gordon, Jonathan Dang, et al. · Integrative Journal of Medical Sciences · 1

Results of SOC-2082 phase 2 study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab as second/third-line therapy for advanced sarcoma.

2023 · Nadezhda Omelchenko, Neal Shiv Chawla, et al. · Journal of Clinical Oncology

Artificial intelligence analysis of CCNG1 expression in tumors: A novel biomarker in development for anti-CCNG1 targeted therapy.

2023 · Erlinda Maria Gordon, Nadezhda Omelchenko, et al. · Journal of Clinical Oncology

PDF

Two year results of blessed: Expanded access for deltarex-g for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual use IND for EARLY-STAGE invasive carcinoma of breast (IND# 19130) .

2022 · Erlinda Maria Gordon, Victoria S. Chua-Alcala, et al. · Journal of Clinical Oncology

Works count: 18

Citation count: 102

H-index: 6

I10-index: 2